Inspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026
Inspire Medical Systems, Inc. (NYSE: INSP) announced it will release its first quarter 2026 financial results after market close on Monday, May 4, 2026. The company's management team will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results and recent business developments. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea with its proprietary Inspire therapy.
Inspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026
Inspire Medical Systems, Inc. (NYSE: INSP) will release its first quarter 2026 financial results after market close on Monday, May 4, 2026. The company's management will host a conference call at 5:00 p.m. Eastern Time to discuss the results and recent business developments. A webcast and replay of the call will be available on Inspire's Investor Relations website.
Inspire Medical to detail Q1 results and business update May 4
Inspire Medical Systems (NYSE: INSP) will release its first quarter 2026 financial results after market close on Monday, May 4, 2026, followed by a management conference call at 5:00 p.m. Eastern Time. The call will discuss financial results and recent business developments, and a webcast will be available for investors. The company has a history of strong performance, including $912.0M revenue in 2025 and revised 2026 guidance of $950M–$1.0B.
A Look At Inspire Medical Systems (INSP) Valuation After CMS Reimbursement Clarity And Rising Hedge Fund Interest
Inspire Medical Systems (INSP) is gaining investor attention following clarity from CMS regarding reimbursement codes for hypoglossal nerve stimulation, which keeps hospital facility fees stable. Despite a recent share price rise, the company is considered 30.8% undervalued with a narrative fair value of $79.42, driven by expectations of expanded coverage and increased reimbursement. Potential risks include a slower Inspire V rollout and shifts in sleep apnea treatments, necessitating a closer look at underlying data for investment decisions.
Aberdeen Group plc Acquires 64,561 Shares of Inspire Medical Systems, Inc. $INSP
Aberdeen Group plc increased its stake in Inspire Medical Systems (NYSE:INSP) by 16.3% in Q4 2025, purchasing 64,561 shares to hold a total of 460,901 shares valued at approximately $42.51 million. Inspire Medical Systems exceeded Q4 earnings expectations with an EPS of $1.65 and revenue of $269.1 million, despite analyst sentiment cooling to a "Hold" rating with an average target price of $104.24. The company has a current market cap of $1.58 billion and its stock opened at $54.93 on Friday.
Hedge Funds View Inspire Medical (INSP) as One of the Best Small-Cap Healthcare Stocks
Hedge funds reportedly consider Inspire Medical Systems Inc. (NYSE: INSP) among the top small-cap healthcare stocks to buy. The company, which specializes in treatments for obstructive sleep apnea (OSA), recently received positive news regarding CMS reimbursement and new HCPCS codes, which analysts view as directionally positive despite some remaining uncertainties. Inspire Medical develops and markets neurostimulation technology for OSA treatment.
JPMorgan Chase & Co. Sells 301,067 Shares of Inspire Medical Systems, Inc. $INSP
JPMorgan Chase & Co. significantly reduced its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 78.9% in the third quarter, selling 301,067 shares and retaining 80,374 shares valued at $5.96 million. Despite this, other institutional investors have recently adjusted their positions in the company, with several increasing their holdings. Inspire Medical Systems currently has a "Hold" consensus rating and an average target price of $104.24, with its stock performance showing a 52-week low of $48.30 and a high of $164.02.
Is It Time To Reassess Inspire Medical Systems (INSP) After Its Steep Multi‑Year Share Price Slump
Inspire Medical Systems (INSP) shares have experienced significant drops over the past year, prompting an assessment of its intrinsic value. According to a Discounted Cash Flow (DCF) analysis, the stock appears to be significantly undervalued by 62.7% at its current price of approximately $51.58 per share, with an estimated intrinsic value of $138.40. Additionally, its current P/E ratio of 10.21x is below both the industry average and Simply Wall St's proprietary Fair Ratio, further suggesting undervaluation.
Inspire Medical Systems Hits New 52-Week Low at $48.78
Inspire Medical Systems, a small-cap company in the Pharmaceuticals & Biotechnology sector, has plummeted to a new 52-week low of $48.78, a significant drop from its high of $164.02. This represents a 68.86% performance decline over the past year, in stark contrast to the S&P 500's 11.87% gain during the same period. The company has a market capitalization of $1,683 million and a P/E ratio of 11.00, with no dividends offered.
Responsive Playbooks and the INSP Inflection
This article analyzes Inspire Medical Systems Inc. (NASDAQ: INSP) using AI models, indicating weak sentiment across all time horizons and supporting a short bias. It identifies a 125.3:1 risk-reward short setup with a targeted 37.2% downside. The analysis provides three institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Inspire Medical Systems stock hits 52-week low at 48.76 USD
Inspire Medical Systems (INSP) stock has fallen to a new 52-week low of $48.73, marking a 68% decrease over the past year. Despite its current undervaluation and oversold RSI, ongoing challenges and market pressures are affecting the company's stock performance. Recent positive news includes CMS adding new HCPCS codes for hypoglossal nerve stimulation procedures, which has led to varied analyst actions though several maintain a "Buy" or "Outperform" rating with adjusted price targets.
FDA Approves Expanded MRI Compatibility for Inspire IV and V
The FDA has approved expanded MRI compatibility for Inspire IV and V systems, allowing patients with these implants to undergo high-resolution 3.0 Tesla MRI scans under specified conditions. This approval builds on previous clearances and provides access to more advanced imaging technology for individuals with moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc. expressed commitment to optimizing the patient experience and strengthening confidence in Inspire therapy.
Inspire Medical Systems Hits New 52-Week Low at $50.00
Inspire Medical Systems, a small-cap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of $50.00, significantly down from its previous high of $164.02, reflecting a 68.66% year-to-date decline. Despite this, the company has a market capitalization of $1,683 million, a P/E ratio of 11.00, and a return on equity of 19.13%, though it does not offer a dividend and has a negative debt-to-equity ratio. This downturn reflects broader industry trends and the company's recent performance metrics.
Vanguard parent reports 0% in Inspire Medical (INSP) after realignment
The Vanguard Group filed an amended Schedule 13G/A for Inspire Medical Systems, Inc. (INSP), reporting 0% beneficial ownership of common stock. This is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately in reliance on SEC guidelines. The filing clarifies reporting lines rather than indicating a change in underlying economic ownership.
Assenagon Asset Management S.A. Invests $24.44 Million in Inspire Medical Systems, Inc. $INSP
Assenagon Asset Management S.A. has acquired a new stake of 264,999 shares, valued at $24.44 million, in Inspire Medical Systems, Inc. (NYSE:INSP) during the fourth quarter. This new investment represents approximately 0.91% of Inspire Medical Systems. The company recently reported strong quarterly earnings, beating analyst estimates with an EPS of $1.65 and revenue of $269.08 million, an increase of 12.2% year-over-year.
Inspire Medical Systems Hits New 52-Week Low at $50.67
Inspire Medical Systems, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 50.67. This decline represents a 67.65% drop over the past year, contrasting significantly with the S&P 500's gain. Despite this, the company has a market capitalization of USD 1,683 million, a P/E ratio of 11.00, and a return on equity of 19.13%.
Why is Inspire (INSP) down 2.4% since last earnings report?
This article from MSN appears to be an incomplete entry, only providing a title and indicating a stock performance drop for Inspire (INSP) since its last earnings report. Without the full content, it's impossible to determine the reasons behind the 2.4% decrease or any contributing factors.
Inspire Medical Systems Governance Vote Arrives As Shares Trade Below Targets
Inspire Medical Systems (NYSE:INSP) shareholders are set to vote on an amendment to the company's Certificate of Incorporation at the upcoming annual general meeting. This governance change is significant given the company's stock is trading well below analyst targets and fair value, with substantial declines over the past year. Investors are urged to closely review the proposed changes to understand their potential impact on board authority and shareholder rights.
Inspire Medical Systems Governance Vote Arrives As Shares Trade Below Targets
Inspire Medical Systems (NYSE:INSP) has proposed an amendment to its Certificate of Incorporation, which shareholders will vote on at the upcoming annual general meeting. This governance change is significant given the company's shares are trading substantially below analyst targets and have seen significant declines over the past year. Investors are urged to closely review the proposed changes to understand their potential impact on board authority and shareholder rights.
Inspire Medical wins expanded MRI indications from FDA
Inspire Medical (NYSE:INSP) has received expanded FDA approval for its Inspire IV and V neuromodulation systems, allowing patients with obstructive sleep apnea (OSA) to undergo high-resolution 3T MRI scans under specific conditions. This builds on a previous approval for 1.5T scans and expands access to powerful imaging technology. The company believes this will strengthen long-term confidence in Inspire therapy for both patients and clinicians.
Inspire Medical Systems eyes growth in the UK market
Inspire Medical Systems is expanding its presence in the UK by making its sleep apnoea technology available at 12 new centers for NHS and elective patients, aiming to increase global usage to over 125,000 patients. The company's implantable pacemaker treats moderate-to-severe obstructive sleep apnoea for those who can't tolerate traditional CPAP treatment. This expansion follows increased clinical adoption and strategic partnerships across Europe, including with the NHS since 2023.
Zacks Research Upgrades Inspire Medical Systems (NYSE:INSP) to Strong-Buy
Zacks Research has upgraded Inspire Medical Systems (NYSE:INSP) from a "hold" to a "strong-buy" rating, though the MarketBeat consensus remains a "Hold" with a target price of $104.24. This upgrade follows strong quarterly results, where INSP beat EPS expectations by $1.65 and reported revenue of $269.1 million, a 12.2% increase year-over-year. Institutional investors hold approximately 94.91% of the stock, with several large funds recently increasing their positions.
Inspire Medical Systems Hits 52-Week Low at $51.59 Amid Market Struggles
Inspire Medical Systems, Inc. (NASDAQ: INSP) has reached a new 52-week low of $51.59, representing a 67.6% decline over the past year, while the S&P 500 saw a 16.12% increase. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, has a market capitalization of $1,683 million, a P/E ratio of 11.00, and a return on equity of 19.13%. Currently, the stock does not offer a dividend, and its previous 52-week high was $172.95.
Inspire (INSP) Raised to Strong Buy: Key Information You Need
Inspire Medical Systems (INSP) has been upgraded to a Zacks Rank #1 (Strong Buy) due to improved earnings forecasts, indicating a positive outlook for the company's stock performance. This rating is based on objective data reflecting changes in earnings expectations, which have historically shown a strong correlation with stock price movements. The Zacks Rank system, which has a proven track record of identifying outperforming stocks, places INSP among the top 5% of companies for estimate revisions, suggesting potential for further gains.
Inspire Medical Systems stock hits 52-week low at $52.68
Inspire Medical Systems (INSP) stock has fallen to a new 52-week low of $52.68, representing a 67% decline over the past year from its high of $172.95. Despite market volatility and recent analyst adjustments following CMS code changes for hypoglossal nerve stimulation, InvestingPro analysis suggests the stock is currently undervalued, holding more cash than debt on its balance sheet. The company's performance and strategic responses will be closely watched by investors.
[ARS] Inspire Medical Systems, In... | INSP SEC Filing - Form ARS
This article announces an ARS SEC filing by Inspire Medical Systems, Inc. (INSP) on March 20, 2026. The filing indicates a low impact and neutral sentiment. It also provides an overview of INSP's stock performance rankings, latest news, and other recent SEC filings.
Inspire Medical surges after KeyBanc sees CMS adding codes for Inspire V implant
Inspire Medical Systems (INSP) stock surged after KeyBanc Capital Markets analyst Arvind Anil noted that the Centers for Medicare & Medicaid Services (CMS) has proposed new CPT codes for the Inspire V device. These codes are expected to improve the company's reimbursement structure by offering better differentiation from the previous OUS-only Inspire II implant.
Wolfe Research downgrades Inspire Medical Systems (INSP)
Wolfe Research has downgraded Inspire Medical Systems (INSP) due to concerns regarding a potentially weakening market and limited growth prospects. The firm believes the shift in sleep apnea treatment, combined with competitive pressures, will restrict Inspire Medical's ability to achieve significant future growth, despite strong past performance.
Form DEF 14A Inspire Medical Systems For: 20 March By Investing.com
This article announces the filing of Form DEF 14A by Inspire Medical Systems for March 20. The DEF 14A filing is a definitive proxy statement providing shareholders with important information ahead of an annual or special meeting. The brief news item refers readers to the filing for further details.
Form DEFA14A Inspire Medical Systems,
This article reports on Inspire Medical Systems' filing of Form DEFA14A with the United States Securities and Exchange Commission. The filing is categorized as "Definitive Additional Materials" under Schedule 14A, indicating information required in a proxy statement. It confirms that Inspire Medical Systems, Inc. is the registrant and no filing fee is required.
Wolfe Research downgrades Inspire Medical Systems (INSP)
Wolfe Research has downgraded Inspire Medical Systems (INSP). Further details about the reasons for the downgrade or the new rating are not available in this snippet.
Inspire Medical Systems (NYSE:INSP) Trading 4.9% Higher - Here's Why
Inspire Medical Systems (NYSE:INSP) saw its shares trade up 4.9% on Wednesday, reaching $57.88 on light volume. Despite recent downgrades from analysts and a mixed consensus rating of "Hold" with a target price of $104.24, the company reported strong quarterly earnings, topping analyst estimates with an EPS of $1.65 and revenue of $269.08 million. Institutional investors have also been active, with several hedge funds increasing their holdings in INSP during recent quarters.
What To Expect From Inspire Medical Systems’s (INSP) Q2 Earnings
This article forecasts Inspire Medical Systems' (INSP) Q2 earnings report. Analysts expect the company to report a Q2 loss per share of $0.09 and revenue of $197.87 million. The report will likely focus on revenue growth, new patient starts, and market expansion.
INSP: Inspire V’s launch, reimbursement clarity, and innovation drive growth amid evolving competition
Inspire Medical Systems, Inc. (INSP) is driving growth through the launch of Inspire V, clarity in reimbursement policies including new C-codes and the WISeR program, and continuous innovation. Leadership emphasized profitable growth, strategic investments, and efficient operations. Despite new competition, Inspire V's strong clinical data and platform upgrades are expected to maintain market leadership.
Bamco Inc. NY Has $14.10 Million Stock Holdings in Inspire Medical Systems, Inc. $INSP
Bamco Inc. NY significantly reduced its stake in Inspire Medical Systems (NYSE:INSP) by 61.4% in the third quarter, now holding 190,023 shares valued at approximately $14.1 million. Inspire Medical Systems recently reported strong earnings, beating analyst expectations with $1.65 EPS and $269.1 million in revenue. Despite a consensus "Hold" rating from analysts and an average price target of $104.24, institutional investors own a substantial 94.91% of the company's stock.
Bamco Inc. NY Reduces Inspire Medical Systems Stock Holdings
Bamco Inc. NY significantly reduced its holdings in Inspire Medical Systems (NYSE:INSP) by 61.4% in the third quarter of 2026, selling 301,729 shares. The investment firm now owns 190,023 shares valued at approximately $14.1 million. This reduction signals potential shifts in investor sentiment regarding Inspire Medical Systems, a leading provider of sleep apnea treatment devices, despite growing adoption of its technology.
Braidwell LP Has $65.57 Million Stock Holdings in Inspire Medical Systems, Inc. $INSP
Braidwell LP significantly increased its stake in Inspire Medical Systems (NYSE:INSP) during the third quarter, now holding 883,747 shares valued at $65.57 million, making it their 15th largest holding. Inspire Medical Systems recently reported strong quarterly earnings, surpassing analyst expectations with $1.65 EPS and $269.08 million in revenue, an increase of 12.2% year-over-year. The stock has an average "Hold" rating from analysts with a consensus price target of $104.24, and institutional investors collectively own 94.91% of the company's shares.
Inspire Medical Systems, Inc. (NYSE:INSP) Receives Average Rating of "Hold" from Brokerages
Inspire Medical Systems, Inc. (NYSE:INSP) has received an average rating of "Hold" from nineteen brokerages, with an average one-year target price of $104.24. Despite beating earnings estimates in its last quarterly report with an EPS of $1.65 against an expected $0.69 and revenue of $269.1 million, the stock is currently trading near $58.64, significantly below the consensus target. Several analysts have recently adjusted their price targets, indicating mixed sentiment.
Integral Health Asset Management LLC Boosts Stake in Inspire Medical Systems, Inc. $INSP
Integral Health Asset Management LLC significantly increased its stake in Inspire Medical Systems, Inc. by 71.4% during the third quarter, now owning 120,000 shares valued at approximately $8.9 million. This move is part of broader institutional investor activity, with other firms also adjusting their holdings in INSP. Inspire Medical Systems recently exceeded earnings expectations, reporting an EPS of $1.65 against an estimated $0.69, and revenue of $269.1 million, while analysts maintain a "Hold" consensus rating with a varied price target of $104.24.
Wolfe Research downgrades Inspire Medical Systems (INSP)
Wolfe Research downgraded Inspire Medical Systems (INSP) from Outperform to Peer Perform. This rating change suggests a more neutral outlook on the company's stock performance from the analyst firm.
Why Is Inspire (INSP) Down 2.4% Since Last Earnings Report?
Inspire Medical Systems (INSP) shares have dropped 2.4% since its last earnings report, underperforming the S&P 500 despite beating Q4 2025 adjusted EPS estimates. The company reported a 10.5% revenue increase year-over-year, reaching $269.1 million, and expanded its gross margin. However, Inspire lowered its revenue guidance for 2026, leading to a downward trend in analyst estimates, and currently holds a Zacks Rank #3 (Hold).
Inspire Medical Systems Q4 2025 slides: revenue hits $912M, projects slower growth
Inspire Medical Systems reported strong Q4 2025 results, with annual revenue reaching $912 million, a 14% year-over-year increase. The company projects slower growth for 2026, anticipating revenue between $950 million and $1 billion (4-10% growth), with a focus on margin expansion and profitability. The successful launch of the Inspire V system positions them well, despite potential reimbursement challenges and market dynamics from new weight loss drugs.
Atika Capital Management LLC Buys 25,700 Shares of Inspire Medical Systems, Inc. $INSP
Atika Capital Management LLC increased its stake in Inspire Medical Systems (NYSE:INSP) by 15.9%, acquiring an additional 25,700 shares. This purchase brings their total holdings to 187,600 shares, valued at approximately $13.92 million, making it their 28th largest holding. Inspire Medical Systems recently reported better-than-expected quarterly earnings and revenue, though analysts maintain a "Hold" rating with an average price target of $104.24.
Inspire Medical Systems, Inc. $INSP Shares Sold by Intech Investment Management LLC
Intech Investment Management LLC decreased its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 83.8% in the third quarter, selling 44,082 shares. Despite this, Inspire Medical Systems reported strong quarterly earnings, beating consensus estimates with $1.65 EPS and $269.08 million in revenue. Institutional investors hold approximately 94.91% of the company's stock, and analysts currently have a consensus "Hold" rating for INSP.
A Look At Inspire Medical Systems (INSP) Valuation After Strong Earnings Beat And Guidance Raise
Inspire Medical Systems (INSP) reported strong Q4 results with revenue exceeding expectations and raised full-year guidance, yet its share price has been under pressure. Despite a recent earnings beat, the stock remains undervalued relative to analyst targets, with a fair value of $124.40 compared to its closing price of $61.89. The article suggests investors consider potential risks like reimbursement setbacks or slower product rollout while highlighting the company's strong projected revenue expansion and profit margins.
A Look At Inspire Medical Systems (INSP) Valuation After Strong Earnings Beat And Guidance Raise
Inspire Medical Systems (INSP) reported strong earnings with revenue growth and raised full-year guidance, yet its share price has been under pressure. Despite a recent dip, analysts suggest the stock is undervalued, with a fair value of $124.40 compared to its closing price of $61.89. The article advises investors to consider both the optimism around projected growth and potential risks like reimbursement issues.
Inspire Medical Systems, Inc. $INSP Shares Purchased by WINTON GROUP Ltd
WINTON GROUP Ltd significantly increased its stake in Inspire Medical Systems (NYSE:INSP) by 1,030.6% in the third quarter, acquiring an additional 83,369 shares. Multiple other institutional investors also added positions, bringing institutional ownership to 94.91%. Despite a strong earnings report and revenue growth, the stock trades well below its 52-week high, holding a "Hold" rating from analysts with a consensus target price of $104.24.
Inspire Medical Systems Stock Analysis: Performance & Investor Outlook 2026 - News and Statistics
Inspire Medical Systems' stock has dropped 22.7% over the past six months, now trading at $62.98. Despite this recent decline, the company has shown significant growth over the last five years, with a 51.2% compounded annual sales growth rate and an expanded free cash flow margin. Investors should consider its relatively small size within the medical instruments industry and its current forward price-to-earnings multiple of 31.4.
Inspire Medical Systems (INSP): Should You Buy, Sell, or Hold After Q4 Results?
Inspire Medical Systems (INSP) has seen a significant 22.7% drop in share price over the last six months, prompting investors to re-evaluate the stock. Despite this, the company exhibits strong financials with impressive five-year compounded annual revenue growth of 51.2% and an improved free cash flow margin of 8.6%. A potential concern is its relatively small scale in the healthcare sector, though this could also enable faster growth.
Inspire Medical Systems (INSP): Buy, Sell, or Hold Post Q4 Earnings?
Inspire Medical Systems (INSP) shares have dropped 22.7% over the last six months to $62.98, prompting investors to question its future. Despite this, the company exhibits strong momentum with a 51.2% compounded annual revenue growth over five years and an expanding free cash flow margin of 8.6%. However, its relatively small revenue base of $912 million limits its distribution channels and market scale, although it also offers potential for faster growth if executed well.
